Multiple Sclerosis – Symptoms, Diagnosis, Treatment of …

Back to TopReferences

Calabresi P. Multiple sclerosis and demyelinating conditions of the central nervous system. In: Goldman L, Ausiello D, eds. Cecil Medicine . 23rd ed. Philadelphia, Pa: Saunders Elsevier;2007:chap 436.

Carroll WM. Oral therapy for multiple sclerosis--sea change or incremental step? N Engl J Med . 2010 Feb 4;362(5):456-8. Epub 2010 Jan 20.

Goodin DS, Cohen BA, O'Connor P, et al. Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology . 2008:71(10):766-73.

Farinotti M, Simi S, Di Pietrantonj C, McDowell N, Brait L, Lupo D, Filippini G. Dietary interventions for multiple sclerosis. Cochrane Database Syst Rev . 2007 Jan 24;(1):CD004192.

Kappos L, Freedman MS, Polman CH, et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet . 2007:370(9585):389-97.

Miller DH, Leary SM. Primary-progressive multiple sclerosis. Lancet Neurol . 2007;6:903-912.

Marriott JJ, Miyasaki JM, Gronseth G, O'Connor PW; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2010 May 4;74(18):1463-70.

See the original post here:
Multiple Sclerosis - Symptoms, Diagnosis, Treatment of ...